利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

117 条记录 (耗时 0.017 秒)

    Methods of treating hypertension and compositions for use therein
    33.
    发明公开
    Methods of treating hypertension and compositions for use therein 审中-公开
    治疗高血压的方法和用于其中的组合物

    公开(公告)号：EP1447089A2

    公开(公告)日：2004-08-18

    申请号：EP04003149.4

    申请日：1999-09-09

    申请人： SCIOS INC. ,  University of Washington

    发明人： Schreiner, George F. ,  Johnson, Richard J.

    IPC分类号： A61K38/19 ,  A61P9/00

    CPC分类号： A61K38/1866

    摘要： The present invention provides methods and compositions for treating hypertension. The methods generally involve administering a factor which increases angiogenesis and/or vascular permeability. Compositions for use in the methods are also provided.

    摘要翻译： 本发明提供了治疗高血压的方法和组合物。 该方法通常涉及施用增加血管生成和/或血管通透性的因子。 还提供了用于该方法的组合物。

    CONTROLLED RELEASE DELIVERY OF PEPTIDE OR PROTEIN
    35.
    发明授权
    CONTROLLED RELEASE DELIVERY OF PEPTIDE OR PROTEIN 有权
    蛋白质或多肽控制下交付

    公开(公告)号：EP1051157B1

    公开(公告)日：2002-01-02

    申请号：EP99904444.9

    申请日：1999-01-28

    申请人： Scios Inc.

    发明人： WANG, Yu-Chang, John ,  YANG, Bing ,  JENNINGS, Robert, N., Jr. ,  PROTTER, Andrew, A.

    IPC分类号： A61K9/16 ,  A61K9/00

    CPC分类号： A61K9/0024 ,  A61K9/2018 ,  A61K9/204

    摘要： Compositions and devices for the controlled release delivery of a peptide or protein drug are produced by dispersing a glassy matrix phase comprising the peptide or protein drug and a thermoprotectant in a bioerodable, biocompatible polymer at a temperature that is below the glass transition temperature of the glassy matrix phase and above the melting point of the polymer. The method and composition of the invention may be employed for the local delivery of angiogenic amounts of basic fibroblast growth factor or vascular endothelial growth factor.

    AGONISTS AND ANTAGONISTS OF PERIPHERAL-TYPE BENZODIAZEPINE RECEPTORS
    36.
    发明公开
    AGONISTS AND ANTAGONISTS OF PERIPHERAL-TYPE BENZODIAZEPINE RECEPTORS 有权
    激动剂和苯二氮卓周围型的拮抗剂

    公开(公告)号：EP1140107A1

    公开(公告)日：2001-10-10

    申请号：EP99966269.5

    申请日：1999-12-15

    申请人： SCIOS INC.

    发明人： JOLY, Alison ,  SCHREINER, George, F. ,  STANTON, Lawrence, W. ,  WHITE, R., Tyler

    IPC分类号： A61K31/55 ,  A61K31/47 ,  A61K39/395 ,  A61K31/435 ,  A61K31/40 ,  A61K31/41 ,  A61P9/00

    CPC分类号： C12Q1/6883 ,  C12Q2600/158

    摘要： The invention concerns the use of agonists and antagonists of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.

    HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS
    39.
    发明公开
    HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS 有权
    HETEROZYCLISCHE衍生物对心力衰竭等疾病的治疗

    公开(公告)号：EP1080078A1

    公开(公告)日：2001-03-07

    申请号：EP99924412.2

    申请日：1999-05-21

    申请人： SCIOS INC.

    发明人： MAVUNKEL, Babu, J. ,  LIU, David, Y. ,  SCHREINER, George, F. ,  LEWICKI, John, A. ,  PERUMATTAM, John, J.

    IPC分类号： C07D235/06 ,  C07D401/06 ,  C07D401/14 ,  C07D209/08 ,  C07D403/06 ,  A61K31/445 ,  A61K31/40 ,  A61K31/41

    CPC分类号： C07D209/08 ,  C07D235/06 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06

    摘要： Compounds of formulae α or β, and the pharmaceutically acceptable salts thereof, wherein each of Z?1 and Z2¿ is independently CR4 or N; where each R4 is independently H or is alkyl (1-6C) or aryl, each of said alkyl or aryl optionally including one or more heteroatoms selected from O, S and N and optionally substituted by one or more of halo, OR, SR, NR¿2?, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl (1-6C), or by one or more CN or =O, or by one or more aliphatic or aromatic 5- or 6-membered rings optionally containing 1-2 heteroatoms; R?1¿ is formula (I); wherein X1 is CO or an isostere thereof; m is 0 or 1; Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl or two Y taken together may form an alkylene (2-3C) bridge; n is 0 or 2; Z3 is CH or N; X2 is CH, CH¿2? or an isostere thereof; and Ar consists of one or two phenyl moieties directly coupled to X?2¿ optionally substituted by halo, nitro, alkyl(1-6C), alkenyl(1-6C), alkynyl(1-6C), CN or CF¿3?, or by RCO, COOR, CONR2, NR2, OR, SR, OOCR or NROCR wherein R is H or alkyl(1-6C) or by phenyl, itself optionally substituted by the foregoing substituents; R?2¿ is H, or is alkyl(1-6C) or aryl, each or said alkyl or aryl optionally including one heteroatome which is O, S or N, and optionally substituted by one or more of halo, OR, SR, NR¿2?, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl(1-6C), alkynyl(1-6C), or by one or more CN or =O, or by one or more aliphatic or aromatic 5- or 6-membered rings optionally containing 1-2 heteroatoms; R?3¿ is H, halo, NO¿2?, alkyl(1-6C), alkenyl(1-6C), alkynyl(1-6C), CN, OR, SR, NR2, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl(1-6C) are disclosed. These compounds are selective inhibitors of p38α kinase.